Last reviewed · How we verify
Interferon alpha-2a recombinant — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Interferon alpha-2a recombinant (Interferon alpha-2a recombinant) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Interferon alpha-2a recombinant TARGET | Interferon alpha-2a recombinant | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Interferon alpha-2a recombinant CI watch — RSS
- Interferon alpha-2a recombinant CI watch — Atom
- Interferon alpha-2a recombinant CI watch — JSON
- Interferon alpha-2a recombinant alone — RSS
Cite this brief
Drug Landscape (2026). Interferon alpha-2a recombinant — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-alpha-2a-recombinant. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab